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OBJECTIVES: Measurement errors in independent vari-
ables may lead to attenuated estimates of their effects and
may contaminate estimates for other covariates in con-
ventional linear regression models (LRM). However, the
direction and magnitude of these biases are difficult to
determine theoretically. Measurement error is a serious
problem in health services research as health status is a
latent variable that can only be measured with error us-
ing proxy variables. This study empirically evaluated the
validity of LRM models in health outcomes research.
METHODS: SEMs with a latent health construct are
proposed and compared with LRM models to examine
the bias of measurement errors in general health status
using data from a study of the impact of pharmacist’s
consultation on both health outcomes and costs (KP/USC
study). Perceived health status at a given time point was
modeled as a latent variable measured by the multiple
scales of the SF-36. RESULTS: The latent health con-
struct with multiple scales of the SF-36 and its SEMs for
health outcomes and costs are empirically supported by
the KP/USC data. SEM estimations of the latent health
construct in both the measurement model and the struc-
tural model were all statistically significant with expected
signs. As predicted, LRM estimates for the SF-36 scales
were attenuated. However, there is no strong evidence
that LRM estimations of treatment effect were contami-
nated by the measurement errors in the SF-36 or that the
simultaneity between health outcomes and costs. CON-
CLUSIONS: Measurement errors in health status vari-
ables may result in attenuated estimates of health status
effects on patient outcomes. Fortunately, careful study
design can eliminate the contamination of treatment ef-
fect estimates due to errors in measuring health status.
Moreover, SEM methods can be used to control both at-
tenuation and resonation biases.
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OBJECTIVES: Accurate determination of disease preva-
lence in large patient populations is difficult. The objec-
tive of this research was to use pharmacy data to develop
an index that estimates the presence and number of
chronic diseases in a managed care population. METH-
ODS: An expert panel evaluated 246 specific medication
classes as to their likelihood to be indicative of a chronic
disease. Those classes identified were then compared
against medical records from two random samples of
persons 18 years of age or older continuously enrolled for
at least one year in a health maintenance organization.
One sample was drawn from all eligible persons (n 
137), while the other sample was restricted to individuals
50 years of age or greater (n  138). A cumulative num-
ber of chronic conditions was designated the chronic dis-
ease index (CDI). Sensitivity and specificity were calcu-
lated for those conditions with prevalence greater than
10% based upon medical record review. RESULTS: The
expert panel designated 54 drug classes as containing
medications used to treat chronic conditions. A total of
5640 medications were dispensed over a 1 year period for
the 275 subjects. The average total number of chronic
conditions via medical record review was 2.89  2.07,
compared to 1.33  1.21 chronic conditions estimated
by medication use. The CDI correlated well with the
number of chronic conditions found via record review
(r  0.735, p  0.0001). The specificity of pharmacy
records to indicate the presence of hypertension, dyslipi-
demia, depression, and diabetes was 79.9%, 99.0%,
90.2%, and 99.6%, respectively. The sensitivity was
90.9%, 49.9%, 77.5%, and 62.2% for hypertension,
dyslipidemia, depression, and diabetes, respectively. CON-
CLUSIONS: The CDI correlates well with documented
chronic conditions. Pharmacy data can be useful in iden-
tifying persons with diagnoses of hypertension, dyslipi-
demia, depression, and diabetes.
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INTRODUCTION: The utility of research results is mea-
sured primarily by its effects on decisions. Underpinning
research are methods appropriate to the question or hy-
pothesis. The role of Classical and Bayesian approaches
remains in dispute in health services research. The goal of
this study was to determine if results differ when both
analytic techniques are used with the same dataset.
METHOD: We searched MEDLINE and related data-
bases for English-language articles published 1 January
1978 through 31 August 1999. We combined Bayesian
and Classical statistics search terms, and their variants,
with randomized control trials (RCTs) and meta analy-
ses. RESULTS: Searches found 18 studies in 14 publica-
tions that met all criteria for review—9 RCTs, 8 meta-anal-
yses and 1 epidemiological estimate. Statistical analyses
using both methods agreed in 5 RCTs, 4 meta-analyses,
and for the epidemiological estimates. For 4 RCTs where
results disagreed, Classical analysis the experimental in-
tervention was efficacious compared to the control and
Bayesian reanalysis concluded the experimental interven-
tion was not proven efficacious. Classical meta-analyses
of the four studies where results disagreed concluded the
experimental intervention was not better than the con-
trol; Bayesian reanalysis concluded the intervention was
efficacious. CONCLUSION: The conventional wisdom
that Classical and Bayesian methods will give similar an-
swers is not supported by this study. Disagreement on
many fundamental beliefs between Classical and Baye-
